FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
News|Articles|May 4, 2020
AMRI Announces Increased Production of Hydroxychloroquine Sulfate for COVID-19 Treatment
Author(s)Pharmaceutical Technology Editors
FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19.
Advertisement
AMRI, a contract research development and manufacturing organization, announced on April 30, 2020 that it will be increasing its production of hydroxychloroquine sulfate (HCQ) API at its Rensselaer, NY, manufacturing facility to assist in the fight against COVID-19.
According to a company press release, FDA approved HCQ for emergency use as a treatment for some hospitalized patients with COVID-19.
“We look forward to working with our drug product producers, government agencies, and associated health authorities globally to ensure access to this API, as needed,” said the company in the press release.
Source:
Advertisement
Related to this article
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: E&L Standards Harmonization
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5